GBP2 acts as a member of the interferon signalling pathway in lupus nephritis

Abstract Lupus nephritis (LN) is a common and serious clinical manifestation of systemic lupus erythematosus. However, the pathogenesis of LN is not fully understood. The currently available treatments do not cure the disease and appear to have a variety of side effects in the long term. The purpose...

Full description

Bibliographic Details
Main Authors: Yuan Zhang, Yinping Liao, Qing Hang, Dong Sun, Ya Liu
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Immunology
Subjects:
Online Access:https://doi.org/10.1186/s12865-022-00520-5
_version_ 1818021979086651392
author Yuan Zhang
Yinping Liao
Qing Hang
Dong Sun
Ya Liu
author_facet Yuan Zhang
Yinping Liao
Qing Hang
Dong Sun
Ya Liu
author_sort Yuan Zhang
collection DOAJ
description Abstract Lupus nephritis (LN) is a common and serious clinical manifestation of systemic lupus erythematosus. However, the pathogenesis of LN is not fully understood. The currently available treatments do not cure the disease and appear to have a variety of side effects in the long term. The purpose of this study was to search for key molecules involved in the LN immune response through bioinformatics techniques to provide a reference for LN-specific targeted therapy. The GSE112943 dataset was downloaded from the Gene Expression Omnibus database, and 20 of the samples were selected for analysis. In total, 2330 differentially expressed genes were screened. These genes were intersected with a list of immune genes obtained from the IMMPORT immune database to obtain 128 differentially expressed immune-related genes. Enrichment analysis showed that most of these genes were enriched in the interferon signalling pathway. Gene set enrichment analysis revealed that the sample was significantly enriched for expression of the interferon signalling pathway. Further analysis of the core gene cluster showed that nine genes, GBP2, VCAM1, ADAR, IFITM1, BST2, MX2, IRF5, OAS1 and TRIM22, were involved in the interferon signalling pathway. According to our analysis, the guanylate binding protein 2 (GBP2), interferon regulatory factor 5 and 2′-5′-oligoadenylate synthetase 1 (OAS1) genes are involved in three interferon signalling pathways. At present, we do not know whether GBP2 is associated with LN. Therefore, this study focused on the relationship between GBP2 and LN pathogenesis. We speculate that GBP2 may play a role in the pathogenesis of LN as a member of the interferon signalling pathway. Further immunohistochemical results showed that the expression of GBP2 was increased in the renal tissues of LN patients compared with the control group, confirming this conjecture. In conclusion, GBP2 is a member of the interferon signalling pathway that may have implications for the pathogenesis of LN and serves as a potential biomarker for LN.
first_indexed 2024-04-14T08:26:20Z
format Article
id doaj.art-934e6b4597c044d69d11aebc8b022448
institution Directory Open Access Journal
issn 1471-2172
language English
last_indexed 2024-04-14T08:26:20Z
publishDate 2022-09-01
publisher BMC
record_format Article
series BMC Immunology
spelling doaj.art-934e6b4597c044d69d11aebc8b0224482022-12-22T02:04:03ZengBMCBMC Immunology1471-21722022-09-0123111110.1186/s12865-022-00520-5GBP2 acts as a member of the interferon signalling pathway in lupus nephritisYuan Zhang0Yinping Liao1Qing Hang2Dong Sun3Ya Liu4Department of Nephrology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Nephrology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Nephrology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Nephrology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Nephrology, The Affiliated Hospital of Xuzhou Medical UniversityAbstract Lupus nephritis (LN) is a common and serious clinical manifestation of systemic lupus erythematosus. However, the pathogenesis of LN is not fully understood. The currently available treatments do not cure the disease and appear to have a variety of side effects in the long term. The purpose of this study was to search for key molecules involved in the LN immune response through bioinformatics techniques to provide a reference for LN-specific targeted therapy. The GSE112943 dataset was downloaded from the Gene Expression Omnibus database, and 20 of the samples were selected for analysis. In total, 2330 differentially expressed genes were screened. These genes were intersected with a list of immune genes obtained from the IMMPORT immune database to obtain 128 differentially expressed immune-related genes. Enrichment analysis showed that most of these genes were enriched in the interferon signalling pathway. Gene set enrichment analysis revealed that the sample was significantly enriched for expression of the interferon signalling pathway. Further analysis of the core gene cluster showed that nine genes, GBP2, VCAM1, ADAR, IFITM1, BST2, MX2, IRF5, OAS1 and TRIM22, were involved in the interferon signalling pathway. According to our analysis, the guanylate binding protein 2 (GBP2), interferon regulatory factor 5 and 2′-5′-oligoadenylate synthetase 1 (OAS1) genes are involved in three interferon signalling pathways. At present, we do not know whether GBP2 is associated with LN. Therefore, this study focused on the relationship between GBP2 and LN pathogenesis. We speculate that GBP2 may play a role in the pathogenesis of LN as a member of the interferon signalling pathway. Further immunohistochemical results showed that the expression of GBP2 was increased in the renal tissues of LN patients compared with the control group, confirming this conjecture. In conclusion, GBP2 is a member of the interferon signalling pathway that may have implications for the pathogenesis of LN and serves as a potential biomarker for LN.https://doi.org/10.1186/s12865-022-00520-5Lupus nephritis (LN)GSEAInterferonProtein‐protein interaction
spellingShingle Yuan Zhang
Yinping Liao
Qing Hang
Dong Sun
Ya Liu
GBP2 acts as a member of the interferon signalling pathway in lupus nephritis
BMC Immunology
Lupus nephritis (LN)
GSEA
Interferon
Protein‐protein interaction
title GBP2 acts as a member of the interferon signalling pathway in lupus nephritis
title_full GBP2 acts as a member of the interferon signalling pathway in lupus nephritis
title_fullStr GBP2 acts as a member of the interferon signalling pathway in lupus nephritis
title_full_unstemmed GBP2 acts as a member of the interferon signalling pathway in lupus nephritis
title_short GBP2 acts as a member of the interferon signalling pathway in lupus nephritis
title_sort gbp2 acts as a member of the interferon signalling pathway in lupus nephritis
topic Lupus nephritis (LN)
GSEA
Interferon
Protein‐protein interaction
url https://doi.org/10.1186/s12865-022-00520-5
work_keys_str_mv AT yuanzhang gbp2actsasamemberoftheinterferonsignallingpathwayinlupusnephritis
AT yinpingliao gbp2actsasamemberoftheinterferonsignallingpathwayinlupusnephritis
AT qinghang gbp2actsasamemberoftheinterferonsignallingpathwayinlupusnephritis
AT dongsun gbp2actsasamemberoftheinterferonsignallingpathwayinlupusnephritis
AT yaliu gbp2actsasamemberoftheinterferonsignallingpathwayinlupusnephritis